Cannabis Sativa Derived Formulation for Transmucosal and Transdermal Delivery

Abstract

A Cannabis sativa-derived formulation for transmucosal and transdermal delivery is disclosed comprising Cannabis sativa-derived compounds nanoencapsulated in phospholipid-based vesicles. A method of encapsulating cannabis-derived compounds in nanosized phospholipid vesicles is also disclosed. Cannabis sativa-derived extracts have enhanced bioavailability when encapsulated in nanosized phospholipid vesicles prior to administration to a subject as compared to non-encapsulated cannabinoids. Also disclosed herein are methods of transmucosal and transdermal administration of the formulation having phospholipid vesicles with nanoencapsulated Cannabis sativa-derived substances.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 62 / 727,996 filed Sep. 6, 2018, which is incorporated by reference into this utility patent application.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]Not applicable.TECHNICAL FIELD OF INVENTION[0003]The present invention relates to encapsulation of cannabinoid compounds, compositions and uses thereof.BACKGROUND OF THE INVENTION[0004]During most of the 20th century, the United States Food and Drug Administration (“FDA”) questioned the safety of cannabis due to its potential for abuse, as well as the adverse cardiovascular, reproductive and pulmonary effects associated with inhalation of any type of smoke. In 1999, the Office of National Drug Control funded a study by the Institute of Medicine to evaluate medicinal uses of cannabis. The outcome of this 1999 study was a recommendation to test alternative cannabinoid delivery systems for medicinal us...

AI Technical Summary

Benefits of technology

The present invention is a composition that uses a phospholipid delivery system to encapsulate Cannabis sativa-derived substances, such as cannabidiol (CBD), tetrahydrocannabinol (THC), and other compounds, for transmucosal or transdermal delivery. The composition can be administered through various methods, such as drops, sprays, or tablets, for oral or transdermal uptake of the Cannabis sativa-derived substances. The phospholipid vesicles with the encapsulated substances are small in size, ranging from 25 nm to 200 nm, and can be easily absorbed through the oral mucosal membrane or the epidermis. The composition can provide a controlled and safe delivery system for Cannabis sativa-derived substances, allowing for effective absorption and utilization by the body.

Problems solved by technology

During most of the 20th century, the United States Food and Drug Administration (“FDA”) questioned the safety of cannabis due to its potential for abuse, as well as the adverse cardiovascular, reproductive and pulmonary effects associated with inhalation of any type of smoke.

Smoking and vaporizing has historically been the route of administration for experienced users, but is not considered the most acceptable route of administration due to exposure to the adverse health consequences of inhaling smoke in the lungs.

These adverse health impacts that arise with smoking and vaporizing make it an unhealthy choice for the administration of a CDB substance.

Recent studies have suggested a clear role for CBD as a medical therapy for many disorders; however, the route of administration severely impacts the bioavailability of the CBD, and in all acceptable cases the bioavailability remains low.

Images